Probiotic Strain Combination for Intestinal Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intestinal inflammation, such as antibiotics, can lead to antibiotic resistance and do not effectively regulate intestinal health, while existing probiotic interventions may not provide sufficient synergistic benefits.
Innovation Solution
A probiotic composition combining Lactobacillus acidophilus LA85 strain (CGMCC No. 1.12735) and Bifidobacterium longum subsp. longum BL36 strain (CGMCC No. 24413) is developed, which synergistically decreases proinflammatory cytokines, increases anti-inflammatory cytokines, enhances intestinal barrier proteins, and reduces oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat intestinal inflammation, then bacterial infection is suppressed, but antibiotic resistance develops
Solution Approach 1:
The patent changes the therapeutic parameter from antibiotic-based treatment to probiotic-based treatment, specifically using Lactobacillus acidophilus LA85 and Bifidobacterium longum subsp. longum BL36 strains. This parameter change maintains treatment effectiveness while eliminating the harmful side effect of antibiotic resistance development
Solution Approach 2:
The patent converts the harmful effect of intestinal inflammation and bacterial translocation into a beneficial outcome by using probiotics to restore intestinal barrier function. The probiotics transform the damaged intestinal environment into a healthy state, reducing proinflammatory cytokines and restoring tight junction proteins
2Reliability
If single probiotic strains are used, then intestinal health is improved, but synergistic benefits are insufficient
Solution Approach 1:
The patent merges two different probiotic strains, Lactobacillus acidophilus LA85 and Bifidobacterium longum subsp. longum BL36, into a composite preparation. This combination produces synergistic effects that enhance therapeutic effectiveness beyond what either strain could achieve alone, addressing the insufficiency of single-strain probiotics
Solution Approach 2:
The patent creates a composite probiotic material combining two distinct bacterial strains with complementary functions. This composite approach leverages the unique properties of each strain to achieve superior therapeutic outcomes, including enhanced reduction of proinflammatory cytokines and improved restoration of intestinal barrier function
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are a probiotic composition for preventing and treating an intestinal inflammation and a use thereof. The probiotic composition for preventing and treating an intestinal inflammation includes a Lactobacillus acidophilus LA85 strain and a Bifidobacterium longum subsp. longum BL36 strain. A brand-new probiotic compounding manner and a brand-new strategy for preventing and treating an intestinal inflammation are creatively developed. It is found that the LA85 strain and the BL36 strain can cooperate, promote each other and exert a synergistic effect in preventing and treating an intestinal inflammation, which is specifically manifested by: decreasing the concentrations of proinflammatory cytokines TNF-α, IL-6 and IL-1β in mouse serum, and increasing the concentration of anti-inflammatory cytokines IL-10; increasing the concentration of urolithin A in mouse serum, and significantly decreasing the concentration of reactive oxygen species in serum; and significantly improving the levels of Zonula Occludens-1, tight junction proteins and Claudin-1 of intestinal barrier indicators in mouse serum.